Small molecule · Degrader of BMI1 (polycomb ring finger oncogene) (BMI1) · developed by PTC Therapeutics
Unesbulin is an orally active agent that targets BMI1, a component of polycomb repressive complex 1, in tumor cells and cancer stem cells. It induces hyper-phosphorylation of BMI1, leading to its degradation and a reduction in proliferation of BMI1-expressing tumor cells. It is being studied in high grade glioma, diffuse intrinsic pontine glioma, and leiomyosarcoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05269355 | Phase 2/3 | Leiomyosarcoma | Terminated | PTCT |
| NCT03605550 | Phase 1 | High Grade Glioma | Active not recruiting | PTCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diffuse Intrinsic Pontine GliomaHigh Grade GliomaLeiomyosarcoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.
See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PTCT catalysts and pipeline →